NorthSea Therapeutics
Naarden
About NorthSea Therapeutics
NorthSea Therapeutics is a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics. The team leverages Structurally Engineered Fatty Acid (SEFA) technology to develop novel and unique therapeutic approaches targeting metabolic, inflammatory and fibrotic diseases. The SEFA technology has generated pipeline candidates with a broad array of inter- and independent biological effects, improving dyslipidemia, insulin resistance, hepatic inflammation and fibrosis in diverse models.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $149.4M
- Funding stage: Late Stage Venture
- Last round: Series C (Dec 2021)
- Website: northseatherapeutics.com
- Phone: +31 (0) 357 60 65 05
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/northsea-therapeutics-57358 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.